1. Home
  2. KPTI vs FSHP Comparison

KPTI vs FSHP Comparison

Compare KPTI & FSHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • FSHP
  • Stock Information
  • Founded
  • KPTI 2008
  • FSHP 2018
  • Country
  • KPTI United States
  • FSHP United States
  • Employees
  • KPTI N/A
  • FSHP N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • FSHP
  • Sector
  • KPTI Health Care
  • FSHP
  • Exchange
  • KPTI Nasdaq
  • FSHP NYSE
  • Market Cap
  • KPTI 81.1M
  • FSHP 90.8M
  • IPO Year
  • KPTI 2013
  • FSHP 2024
  • Fundamental
  • Price
  • KPTI $0.63
  • FSHP $10.22
  • Analyst Decision
  • KPTI Strong Buy
  • FSHP
  • Analyst Count
  • KPTI 4
  • FSHP 0
  • Target Price
  • KPTI $5.00
  • FSHP N/A
  • AVG Volume (30 Days)
  • KPTI 694.6K
  • FSHP 8.8K
  • Earning Date
  • KPTI 02-27-2025
  • FSHP 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • FSHP N/A
  • EPS Growth
  • KPTI N/A
  • FSHP N/A
  • EPS
  • KPTI N/A
  • FSHP 0.11
  • Revenue
  • KPTI $148,442,000.00
  • FSHP N/A
  • Revenue This Year
  • KPTI $5.47
  • FSHP N/A
  • Revenue Next Year
  • KPTI $6.33
  • FSHP N/A
  • P/E Ratio
  • KPTI N/A
  • FSHP $90.25
  • Revenue Growth
  • KPTI 1.77
  • FSHP N/A
  • 52 Week Low
  • KPTI $0.58
  • FSHP $9.99
  • 52 Week High
  • KPTI $1.70
  • FSHP $10.25
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • FSHP N/A
  • Support Level
  • KPTI $0.60
  • FSHP N/A
  • Resistance Level
  • KPTI $0.70
  • FSHP N/A
  • Average True Range (ATR)
  • KPTI 0.05
  • FSHP 0.00
  • MACD
  • KPTI -0.00
  • FSHP 0.00
  • Stochastic Oscillator
  • KPTI 46.61
  • FSHP 0.00

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: